Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCS-2 extension in BPH/LUTS
NCT01002222Phase 3Completed
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Start
- Jan 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of MCS-2 in benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), sponsored by Health Ever Bio-Tech Co., Ltd. Primary endpoint: Treatment-Emergent Adverse Events at 36 weeks. Started Jan 2011; status: completed.
02
Drugs
MCS-2
03
Conditions
benign prostatic hyperplasia (BPH)lower urinary tract symptoms (LUTS)
Beyond the preview
Go deeper on NCT01002222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01002222.